Sinotau Pharmaceutical Group
Clinical trials sponsored by Sinotau Pharmaceutical Group, explained in plain language.
-
Radioactive drug shows promise for hard-to-treat nerve tumors
Disease control OngoingThis study tests a radioactive drug called Lutetium-177 oxodotreotide in 74 people with advanced neuroendocrine tumors that cannot be removed by surgery and have gotten worse. The drug targets tumor cells to control the disease. The main goals are to check safety and see how many…
Phase: PHASE2, PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
Radioactive drug shows promise against hard-to-treat gut tumors
Disease control OngoingThis phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high dose of the standard drug octreotide in 196 people with advanced neuroendocrine tumors (NETs) that could not be removed by surgery. The goal was to see which treatment better delayed tum…
Phase: PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated May 22, 2026 14:05 UTC